Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
The Pharma Letter3d
Semaglutide and tirzepatide potential to transform type 1 diabetes treatment
A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...
Fierce Pharma7d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Verywell Health on MSN14d
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage
Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...
ConsumerAffairs10d
Eli Lilly providing lower-priced Zepbound offerings
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
US judge bars copies of Lilly weight-loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
The GLP-1 shortages are over. What happens next?
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...